Japanese Launch of Leqembi® Pen: A Breakthrough in Alzheimer's Treatment

Leqembi® Pen: A New Era in Alzheimer’s Treatment in Japan

On November 13, 2026, Eisai, a partner of BioArctic, announced a significant advancement in Alzheimer’s treatment with the Japanese launch of Leqembi Pen. This subcutaneous formulation of lecanemab, intended for treating early-stage Alzheimer’s disease, marks Japan as the second nation after the United States to approve this innovative treatment option.

What is Leqembi Pen?

Leqembi Pen gained regulatory approval in Japan on September 16, 2026. It has also been added to the National Health Insurance (NHI) Drug Price List in Japan, making it the first anti-amyloid treatment that can be self-administered at home. The treatment utilizes an autoinjector, providing patients with the ability to self-administer the drug once weekly, which represents a notable improvement in terms of flexibility compared to the traditional intravenous (IV) administration required every two weeks in a clinical setting.

The recommended dosing regimen is 500 mg once a week, delivered through two injection pens, which allows for greater convenience for patients. With the Leqembi Pen, those managing the challenges of Alzheimer’s can reduce clinic visitation and streamline treatment integration into their daily lives. This home administration option not only eases the logistical burden of frequent hospital visits but also has the potential to conserve healthcare resources dedicated to IV administration.

Enhanced Patient Autonomy

With the proper education and training, patients or designated caregivers can administer Leqembi Pen under physician guidance. This empowers patients and their support systems, preserving dignity and promoting independence in managing their condition. However, it maintains essential safety protocols, as MRI monitoring for amyloid-related imaging abnormalities (ARIA) is still required before initiating treatment and periodically thereafter.

Global Impact of Leqembi

Leqembi is the result of a strategic collaboration between BioArctic and Eisai, aiming to combat Alzheimer’s disease – a devastating condition that affects millions worldwide. The treatment specifically targets aggregated soluble and insoluble forms of amyloid-beta (Aβ), the protein primarily responsible for forming the plaques found in the brains of Alzheimer’s patients. Its progressive availability in 53 countries signifies a broader commitment to combatting neurodegenerative diseases globally, showcasing a paradigm shift in treatment methodologies for Alzheimer’s disease.

In the U.S., the treatment has already been well-received, with a subcutaneous administration method approved for ease of use. Application for the same formulation is under review in several countries, highlighting the diverse efforts to make this critical innovation accessible to a wider audience.

Research and Development Continuation

Eisai has been active in this field since 2005, particularly noted for its Phase 3 clinical study (AHEAD 3-45), which began in July 2020. This study focuses on individuals with preclinical Alzheimer’s who exhibit elevated amyloid levels but show no clinical signs of the disease. The ongoing commitment of these research initiatives showcases the potential for further innovations in Alzheimer’s treatment, with the Tau NexGen clinical study also incorporating lecanemab as a core component of its framework.

The collaboration between BioArctic and Eisai has a strong emphasis on innovation, not only with Leqembi but also other potential treatments targeting conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). This dedication to addressing severe diseases afflicting the aging population underscores the urgency and necessity of pioneering advancements in the field of neuroscience.

Conclusion

The launch of Leqembi Pen in Japan marks a significant milestone in Alzheimer’s treatment, reflecting a growing recognition of the importance of patient-centered care. By offering at-home administration, it enhances patients' quality of life and empowers them to take charge of their treatment. As the healthcare community continues to address the complexities of Alzheimer’s disease, innovations like Leqembi Pen pave the way for a future with more accessible and effective treatments for patients and caregivers alike.